FDA sets new date for panel review of HIV lipodystrophy drug
This article was originally published in Scrip
Executive Summary
The US FDA has announced a new meeting date for an advisory panel review of Theratechnologies' proposed HIV lipodystrophy drug, Egrifta (tesamorelin acetate) and the endocrinologic and metabolic drugs advisory committee will now meet on 27 May.